Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study

Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study

BackgroundThe oral, selective, and potent small molecule cyclin-dependent kinases (CDK) 4/6 inhibitor (CDK4/6i) abemaciclib has demonstrated efficacy in advanced breast cancer and high-risk early breast cancer. This Phase 1b study evaluated the safety, tolerability, pharmacokinetics, and antitumor a...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sara M. Tolaney, Komal Jhaveri, Teresa Helsten, Shannon L. Puhalla, Alison Conlin, E. Claire Dees, Muralidhar Beeram, Sonya C. Chapman, Andrew Lithio, Lacey M. Litchfield, Matthew P. Goetz
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-03-01
Series:	Frontiers in Oncology
Subjects:	abemaciclib metastatic breast cancer CDK4 CDK6 everolimus exemestane
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1555921/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Abemaciclib and Letrozole in Metastatic Male Breast Cancer
by: Leon Schönfeld, et al.
Published: (2024-11-01)

Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunities
by: Mashael Algethami, et al.
Published: (2025-08-01)

Abemaciclib treatment patterns and outcome in HR+/HER2- locally advanced or metastatic breast cancer: a real-world study from Kuwait and Lebanon
by: Anwar Al Nouri, et al.
Published: (2025-06-01)

Risk factors for adverse reactions caused by abemaciclib in breast cancer therapy
by: Xianghua Quan, et al.
Published: (2025-06-01)

Development of CDK4/6 Inhibitors in Gastrointestinal Cancers: Biomarkers to Move Forward
by: Ioannis A. Voutsadakis
Published: (2025-06-01)

A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer
by: Jialin Zhang, et al.
Published: (2025-03-01)

The ICEDORA study: clinical and demographic characteristics and treatment regimens of patients with HR+ HER2- locally advanced or metastatic breast cancer receiving CDK4/6 inhibitors in real clinical practice
by: I. E. Khatkov, et al.
Published: (2025-07-01)

Knockout of cyclin-dependent kinases 8 and 19 leads to depletion of cyclin C and suppresses spermatogenesis and male fertility in mice
by: Alexandra V Bruter, et al.
Published: (2025-04-01)

Healthcare Resource Utilization and Cost Comparison Between Palbociclib, Abemaciclib, and Ribociclib Among Patients with HR+/HER2− Metastatic Breast Cancer
by: Pluard TJ, et al.
Published: (2025-03-01)

Our Experience and Literature Update Regarding Concomitant Radiotherapy with CDK4/6 Inhibitors and Hormonal Therapy in Metastatic Breast Cancer
by: Laura-Florentina Rebegea, et al.
Published: (2025-05-01)

Survival benefit from abemaciclib in non–small cell lung cancer by Kirsten rat sarcoma–mutation gene expression subtype: retrospective analysis from the JUNIPER Trial
by: Jiangang Liu, et al.
Published: (2025-03-01)

Factors Affecting the Survival of Metastatic Breast Cancer Patients Treated with CDK 4/6 Inhibitors
by: Zehra Sucuoğlu İşleyen, et al.
Published: (2025-07-01)

Abemaciclib in combination with endocrine therapy for the treatment of HR-positive/HER2-negative locally advanced/metastatic breast cancer in the UK: an observational study
by: Judy King, et al.
Published: (2025-07-01)

Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study
by: Seda Kahraman, et al.
Published: (2024-12-01)

CDK4/6 inhibitors in the treatment of metastatic breast cancer. Choosing optimal therapy for estrogen-receptor-positive HER2-negative metastatic breast cancer: analysis of doctors’ preferences (“Prometheus”) in Russia – first results of the survey
by: E. V. Artamonova, et al.
Published: (2021-01-01)

Escalation and De-Escalation Strategies for Endocrine Therapy in Early-Stage Breast Cancer
by: Al-Batsh T, et al.
Published: (2025-03-01)

Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
by: Paola Zagami, et al.
Published: (2025-02-01)

An in silico and in vitro approach for understanding CDK2 expression pattern and prognostic implications in breast cancer
by: Fatima Manhas, et al.
Published: (2025-05-01)

Escalation of adjuvant endocrine therapy for early hormone-dependent HER2-negative breast cancer: to whom, when and why?
by: I. V. Kolyadina
Published: (2024-05-01)

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them
by: L. Foffano, et al.
Published: (2025-02-01)

Ribociclib-Induced Delayed Dermatological Reaction: Case Report of a Rare Adverse Effect and Review of Literature
by: Bhavika Kothari, et al.

Unraveling a novel therapeutic facet of Etravirine to confront Hepatocellular Carcinoma via disruption of cell cycle
by: Gouri Nair, et al.
Published: (2025-02-01)

Dengue virus modulates critical cell cycle regulatory proteins in human megakaryocyte cells
by: Swarnendu Basak, et al.
Published: (2025-05-01)

Arcyriaflavin A, a cyclin D1/CDK4 inhibitor, suppresses tumor growth, migration, and invasion of metastatic melanoma cells
by: Dokyeong Kim, et al.
Published: (2025-02-01)

Abemaciclib induces G1 arrest and lysosomal dysfunction in canine melanoma cells: synergistic effects with fenbendazole
by: Se-Hoon Kim, et al.
Published: (2025-06-01)

Clinical Benefit and Safety of Palbociclib in Hormone Positive Breast Cancer with Visceral Metastasis: Real-World Experience from a Tertiary Cancer Center
by: Sandeep K. S, et al.
Published: (2025-04-01)

Case Report: Abemaciclib‐Induced Chronic Renal Failure
by: Lu Lin, et al.
Published: (2025-06-01)

A rational approach to dose reduction of CDK4/6 inhibitors in the treatment of patients with advanced breast cancer: A narrative Review
by: I. N. Dyakov, et al.
Published: (2025-07-01)

Stabilization of GTSE1 by cyclin D1–CDK4/6-mediated phosphorylation promotes cell proliferation with implications for cancer prognosis
by: Nelson García-Vázquez, et al.
Published: (2025-04-01)

Therapeutic Prospects of Abemaciclib for Patients with Endometrial Cancer
by: Ahmad Awada, et al.
Published: (2024-09-01)

Comparative long-term outcomes of first-line CDK4/6 inhibitors plus endocrine therapy versus endocrine therapy in patients with HR+/HER2-metastatic or advanced breast cancer: a meta-analysis
by: Xiaojian Wang, et al.
Published: (2025-07-01)

Validation of an LC-MS/MS Method for the Simultaneous Intracellular Quantification of the CDK4/6 Inhibitor Abemaciclib and the EZH2 Inhibitors GSK126 and Tazemetostat
by: Stefan Senekowitsch, et al.
Published: (2025-03-01)

Annona squamosa (custard apple) leaves extract mitigates abemaciclib-induced liver injury (AILI) in male rats
by: Lashin S. Ali, et al.
Published: (2025-12-01)

Identification of new inhibitors of the kinase activity of CDK2 and CDK9 by molecular modeling and high-efficiency screening
by: G.V. Andrianov, et al.
Published: (2021-12-01)

Safety and Efficacy of Everolimus Plus Exemestane in Postmenopausal Women with Treatment-refractory Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer: Analysis from EVEREXES Taiwan Subset
by: Yuan-Ching Chang, et al.
Published: (2023-07-01)

PRACTICAL ASPECTS OF ADMINISTERING CYCLIN-DEPENDENT KINASES INHIBITORS: EFFICACY AND TOLERABILITY
by: E. V. Artamonova
Published: (2018-04-01)

Synthesis, biological evaluation, and in silico studies of new CDK2 inhibitors based on pyrazolo[3,4-d]pyrimidine and pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine scaffold with apoptotic activity
by: Asmaa A. Mandour, et al.
Published: (2022-12-01)

Validation of a hypomorphic variant in CDK13 as the cause of CHDFIDD with autosomal recessive inheritance through determination of an episignature
by: Jan Fischer, et al.
Published: (2025-01-01)

Pembrolizumab promotes degradation of cyclin dependent kinase 6 and suppresses ovarian cancer progression in vitro
by: Yi Wu, et al.
Published: (2025-07-01)

CDK4/6 inhibitors synergize with radiotherapy to prime the tumor microenvironment and enhance the antitumor effect of anti-PD-L1 immunotherapy in triple-negative breast cancer
by: Wen-Chi Yang, et al.
Published: (2025-08-01)